NasdaqCM:VKTXBiotechs
The Bull Case For Viking Therapeutics (VKTX) Could Change Following Fresh Validation Of Oral Obesity Drugs
In recent weeks, analysts reiterated positive views on Viking Therapeutics after competitor Eli Lilly reported supportive Phase 3 results for a similar oral obesity therapy, reinforcing confidence in Viking’s lead candidate VK2735 and its broader metabolic pipeline.
This combination of bullish analyst coverage and external clinical validation highlights how Viking, still without approved products, is increasingly viewed as a potential participant in large obesity and NASH markets.
We’ll now...